和鉑醫藥-B(02142.HK):受託人根據股份獎勵計劃購買770萬股
格隆匯12月30日丨和鉑醫藥-B(02142.HK)發佈公吿,2021年12月6日至該公吿日期期間,受託人已根據股份獎勵計劃及計劃規則,按平均價格約8.22港元從市場上購買合共770萬股,以信託方式為參與者的利益持有。所購買的股份將用作股份獎勵計劃參與者的獎勵。根據計劃規則,儘管受託人為根據股份獎勵計劃以信託方式持有的股份的合法登記持有人,但受託人將不得行使其於信託項下所持有的有關股份所附的任何投票權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.